The latest news in weight-loss drugs turned negative this week. What a difference a month makes in the never-boring world of weight-loss drugs. Last month—when the news was so bullish that semaglutides (or GLP-1s, as this class of drugs is known) such as Ozempic and Wegovy might also cure all addiction—Morgan Stanley analysts raised their estimate for the size of the anti-obesity market to $77 billion worldwide in 2030, up $23 billion from the previous forecast.Read Full Story